Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial

Adjuvant Therapy ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Multicentre Phase ◽

Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30088-8 ◽

2017 ◽

Vol 18 (3) ◽

pp. 371-383 ◽

Cited By ~ 21

Author(s):

Pin Zhang ◽

Tao Sun ◽

Qingyuan Zhang ◽

Zhongyu Yuan ◽

Zefei Jiang ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Controlled Trial ◽

Metastatic Breast ◽

Open Label ◽

Phase 3 ◽

Heavily Pretreated ◽

Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial

The Lancet ◽

10.1016/s0140-6736(09)61523-3 ◽

2009 ◽

Vol 374 (9707) ◽

pp. 2055-2063 ◽

Cited By ~ 163

Author(s):

Kathy S Albain ◽

William E Barlow ◽

Peter M Ravdin ◽

William B Farrar ◽

Gary V Burton ◽

...

Keyword(s):

Breast Cancer ◽

Adjuvant Chemotherapy ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Node Positive ◽

Randomised Controlled ◽

Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial

Yearbook of Oncology ◽

10.1016/s1040-1741(10)79516-6 ◽

2010 ◽

Vol 2010 ◽

pp. 19-21

Author(s):

J.T. Thigpen

Keyword(s):

Breast Cancer ◽

Adjuvant Chemotherapy ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Node Positive ◽

Randomised Controlled ◽

Faculty Opinions recommendation of Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1166102.628092 ◽

2009 ◽

Author(s):

Jim Orr ◽

Fadi Abu Shahin

Keyword(s):

Ovarian Cancer ◽

Controlled Trial ◽

Advanced Ovarian Cancer ◽

Open Label ◽

Phase 3 ◽

Dose Dense ◽

Faculty Opinions recommendation of Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.13827960.15267062 ◽

2012 ◽

Author(s):

Weijing Sun ◽

Davendra Sohal

Keyword(s):

Gastric Cancer ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

D2 Gastrectomy ◽

Faculty Opinions recommendation of 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718043513.793482079 ◽

2013 ◽

Author(s):

Ana Maria Gonzalez-Angulo

Keyword(s):

Breast Cancer ◽

Controlled Trial ◽

Her2 Positive ◽

Open Label ◽

Adjuvant Trastuzumab ◽

Her2 Positive Breast Cancer ◽

Randomised Controlled ◽

Upfront FOLFOXIRI Plus Bevacizumab and Reintroduction after Progression versus mFOLFOX6 Plus Bevacizumab Followed by FOLFIRI Plus Bevacizumab in the Treatment of Patients with Metastatic Colorectal Cancer (TRIBE2): A Multicentre, Open-Label, Phase 3, Randomised Controlled Trial by GONO

SSRN Electronic Journal ◽

10.2139/ssrn.3478102 ◽

2019 ◽

Author(s):

Chiara Cremolini ◽

Carlotta Antoniotti ◽

Daniele Rossini ◽

Sara Lonardi ◽

Fotios Loupakis ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial

The Lancet Oncology ◽

10.1016/s1470-2045(21)00027-9 ◽

2021 ◽

Author(s):

Angela Lamarca ◽

Daniel H Palmer ◽

Harpreet Singh Wasan ◽

Paul J Ross ◽

Yuk Ting Ma ◽

...

Keyword(s):

Biliary Tract Cancer ◽

Controlled Trial ◽

Symptom Control ◽

Second Line ◽

Open Label ◽

Phase 3 ◽

Tract Cancer ◽

Folfox Chemotherapy ◽

Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial

Annals of Oncology ◽

10.1093/annonc/mdw055 ◽

2016 ◽

Vol 27 (5) ◽

pp. 806-812 ◽

Cited By ~ 8

Author(s):

N. Zdenkowski ◽

J.F. Forbes ◽

F.M. Boyle ◽

G. Kannourakis ◽

P.G. Gill ◽

...

Keyword(s):

Breast Cancer ◽

Endocrine Therapy ◽

Hormone Receptor ◽

Controlled Trial ◽

Adjuvant Endocrine Therapy ◽

Open Label ◽

Hormone Receptor Positive ◽

Randomised Controlled ◽

Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial

The Lancet ◽

10.1016/s0140-6736(09)61157-0 ◽

2009 ◽

Vol 374 (9698) ◽

pp. 1331-1338 ◽

Cited By ~ 494

Author(s):

Noriyuki Katsumata ◽

Makoto Yasuda ◽

Fumiaki Takahashi ◽

Seiji Isonishi ◽

Toshiko Jobo ◽

...

Keyword(s):

Ovarian Cancer ◽

Controlled Trial ◽

Advanced Ovarian Cancer ◽

Open Label ◽

Phase 3 ◽

Dose Dense ◽